#complementinhibition
LightNews LightNews
sigtrans-sttt.bsky.social
#RepeatedMildClosedHeadInjury triggers sustained #neuroimmune and complement activation—marked by #microglial recruitment and #CognitiveImpairment—while post-injury #ComplementInhibition significantly mitigates these pathological changes.

#CoverPage in #STTT: doi.org/10.1038/s413...
January 2, 2026 at 11:00 PM
omeroscorp.bsky.social
Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
December 24, 2025 at 2:53 PM
sigtrans-sttt.bsky.social
#RepeatedMildClosedHeadInjury activates complement-driven neuroimmune responses, induces #microglial dysfunction and #neurodegenerative pathways, and post-injury #ComplementInhibition can reverse these effects,

#OpenAccess in #STTT: doi.org/10.1038/s413...
November 25, 2025 at 3:00 PM
drsumanbehera.bsky.social
"The activation of the #complement system is not necessarily harmful in all settings, and hence #complementinhibition is not necessarily beneficial in all conditions."
#kireport

The Rational Use of Complement Inhibitors in Kidney Diseases

kireports.org/article/S2468-…
The Rational Use of Complement Inhibitors in Kidney Diseases
The development of complement inhibitors represented one of the major breakthroughs in clinical nephrology in the last decade. Complement inhibition has dramatically transformed the outcome of one of the most severe kidney diseases, the atypical hemolytic uremic syndrome (aHUS), a prototypic complement-mediated disorder. The availability of complement inhibitors has also opened new promising perspectives for the management of several other kidney diseases in which complement activation is involved to a variable extent.
www.kireports.org
March 28, 2025 at 3:12 AM
hemehub.bsky.social
🌟🔎Today’s questions!

Swipe to see the answers and explanations!

#PNH #BreakthroughHemolysis #IVH #LDH #Haptoglobin #Bilirubin #HemolysisMarkers #ComplementSystem #C5 #Eculizumab #ComplementInhibition #Hematology #HemeOnc #RareDisease #ClinicalMedicine #MedicalEducation #MedEd #HEMEHUB
May 18, 2026 at 9:11 PM
hemehub.bsky.social
🩸🚀Today’s questions!

Swipe to see the answers and explanations!

#PNH #ComplementInhibition #FactorBInhibitor #InfectionRisk #Hematology #HemeOnc #IntravascularHemolysis #Reticulocytosis #LDH #BreakthroughHemolysis #BoneMarrowResponse #MedicalEducation #ClinicalEducation #MedEd #HEMEHUB
May 16, 2026 at 8:32 PM
hemehub.bsky.social
🩺🔍Today’s clinical questions!

Swipe to see the answers and explanations!

#PNH #ComplementInhibition #C3Inhibitors #FactorBInhibitors #Pegcetacoplan #Iptacopan #BreakthroughHemolysis #ComplementCascade #Hemolysis #ClinicalHematology #Hematology #HemeOnc #ClinicalCases #RareDiseases #HEMEHUB
May 12, 2026 at 1:41 AM
hemehub.bsky.social
🩸 Facts about PNH & Breakthrough Hemolysis:

Proximal inhibition, complement regulation, and evolving strategies in disease control.

#PNH #ComplementSystem #ComplementInhibition #C3Inhibitors #Pegcetacoplan #Iptacopan #BoneMarrowFailure #RareDiseases #Hematology #HemeOnc #MedicalEducation #HEMEHUB
May 12, 2026 at 1:40 AM
hemehub.bsky.social
💡🚀Today’s clinical questions!

Swipe to see the answers and explanations!

#PNH #ComplementSystem #BreakthroughHemolysis #C5Inhibitors #Ravulizumab #ComplementInhibition #ExtravascularHemolysis #Pegcetacoplan #Danicopan #Iptacopan #Eculizumab #Hematology #HemeOnc #HEMEHUB
May 9, 2026 at 10:44 PM
hemehub.bsky.social
🩸🌟First clinical questions of the month!

Swipe to see the answers and explanations!

#PNH #BreakthroughHemolysis #Eculizumab #Ravulizumab #ComplementInhibition #Hematology #Hemolysis #LDH #Pharmacokinetics #Pharmacodynamics #Influenza #ComplementActivation #RareDiseases #HemeOnc #HEMEHUB
May 6, 2026 at 7:36 PM
sigtrans-sttt.bsky.social
Targeting complement inhibition improves pathological and cognitive outcomes following closed head injury, supporting complement signaling as a therapeutic intervention pathway.
doi.org/10.1038/s413...
#ComplementSystem #ComplementInhibition #ClosedHeadInjury #Neuroinflammation #Neuroprotection
June 5, 2026 at 10:09 AM
drsumanbehera.bsky.social
"The activation of the #complement system is not necessarily harmful in all settings, and hence #complementinhibition is not necessarily beneficial in all conditions."
#kireport

The Rational Use of Complement Inhibitors in Kidney Diseases

kireports.org/article/S2468-…
The Rational Use of Complement Inhibitors in Kidney Diseases
The development of complement inhibitors represented one of the major breakthroughs in clinical nephrology in the last decade. Complement inhibition has dramatically transformed the outcome of one of the most severe kidney diseases, the atypical hemolytic uremic syndrome (aHUS), a prototypic complement-mediated disorder. The availability of complement inhibitors has also opened new promising perspectives for the management of several other kidney diseases in which complement activation is involved to a variable extent.
www.kireports.org
March 28, 2025 at 3:39 AM